mitoxantrone has been researched along with Devic Disease in 14 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the benefit of mitoxantrone treatment in patients with relapsing neuromyelitis optica." | 9.12 | Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). ( Bakshi, R; Feichter, J; Lincoff, N; Napoli, SQ; Ramanathan, M; Sharma, J; Weinstock-Guttman, B, 2006) |
| "The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD)." | 9.01 | Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( Enriquez, CAG; Espiritu, AI; Pasco, PMD, 2019) |
| "To evaluate the efficacy of mitoxantrone (MTX) on clinical and neuroradiological parameters of patients who had a relapse of neuromyelitis optica spectrum (NMOS) within the 12 previous months." | 7.79 | Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. ( Cabre, P; Jeannin, S; Marignier, R; Merle, H; Olindo, S; Smadja, D, 2013) |
| "To evaluate the efficacy and safety of mitoxantrone hydrochloride and determine how it exhibits a differential inhibitory effect on subsets of B cells in patients with highly relapsing neuromyelitis optica (NMO)." | 7.77 | Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. ( Kim, HJ; Kim, SH; Kim, W; Li, XF; Park, MS; Sohn, EH, 2011) |
| "To evaluate the benefit of mitoxantrone treatment in patients with relapsing neuromyelitis optica." | 5.12 | Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). ( Bakshi, R; Feichter, J; Lincoff, N; Napoli, SQ; Ramanathan, M; Sharma, J; Weinstock-Guttman, B, 2006) |
| "The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD)." | 5.01 | Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( Enriquez, CAG; Espiritu, AI; Pasco, PMD, 2019) |
| " Pediatric Multiple Sclerosis seems to respond better to immunosuppressant agents (Mitoxantrone, Cyclophosphamide, Natalizumab), as well as Neuromyelitis optica (Rituximab, Mycofenolate)." | 4.91 | The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data. ( Cocuzza, S; Di Mauro, P; Falsaperla, R; Ledda, C; Lubrano, R; Matin, N; Pavone, P; Serra, A; Tabatabaie, O; Vitaliti, G, 2015) |
| " Patients with prolonged memory B-cell depletion after RTX, previous mitoxantrone history, hypo-IgG at baseline, or obesity were at risk of developing RTX-induced hypogammaglobulinemia." | 4.12 | Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders: A 14-Year Real-Life Experience. ( Hyun, JW; Kim, HJ; Kim, KH; Kim, SH; Park, NY, 2022) |
| "To evaluate the efficacy of mitoxantrone (MTX) on clinical and neuroradiological parameters of patients who had a relapse of neuromyelitis optica spectrum (NMOS) within the 12 previous months." | 3.79 | Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. ( Cabre, P; Jeannin, S; Marignier, R; Merle, H; Olindo, S; Smadja, D, 2013) |
| "To evaluate the efficacy and safety of mitoxantrone hydrochloride and determine how it exhibits a differential inhibitory effect on subsets of B cells in patients with highly relapsing neuromyelitis optica (NMO)." | 3.77 | Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. ( Kim, HJ; Kim, SH; Kim, W; Li, XF; Park, MS; Sohn, EH, 2011) |
| "Preventing relapses in neuromyelitis Optica spectrum disorder (NMOSD) is a primary goal." | 2.44 | Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean. ( Bérard, N; Cabre, P; Chaumont, H; Karam, JP; Lannuzel, A; Lobjois, Q; Signate, A; Tressieres, B, 2024) |
| "191 attacks occurred during any of the treatments (annual relapse rate=0." | 1.46 | Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. ( Aktas, O; Angstwurm, K; Berthele, A; Borisow, N; Faiss, J; Fischer, K; Friede, T; Gahlen, A; Geis, C; Hartung, HP; Havla, J; Hellwig, K; Hemmer, B; Hofstadt-van Oy, U; Jarius, S; Kleinschnitz, C; Kleiter, I; Krumbholz, M; Kümpfel, T; Lauda, F; Linker, RA; Marziniak, M; Mayer, C; Neuhaus, O; Pache, F; Paul, F; Ringelstein, M; Ruprecht, K; Schuster, S; Schwab, M; Stangel, M; Stellmann, JP; Then Bergh, F; Trebst, C; Tumani, H; Wildemann, B; Young, KL; Zeltner, L; Zettl, U; Ziemann, U, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, SH | 3 |
| Park, NY | 1 |
| Kim, KH | 1 |
| Hyun, JW | 1 |
| Kim, HJ | 3 |
| Chaumont, H | 1 |
| Bérard, N | 1 |
| Karam, JP | 1 |
| Lobjois, Q | 1 |
| Tressieres, B | 1 |
| Signate, A | 1 |
| Lannuzel, A | 1 |
| Cabre, P | 2 |
| Stellmann, JP | 1 |
| Krumbholz, M | 1 |
| Friede, T | 1 |
| Gahlen, A | 1 |
| Borisow, N | 1 |
| Fischer, K | 1 |
| Hellwig, K | 1 |
| Pache, F | 1 |
| Ruprecht, K | 1 |
| Havla, J | 1 |
| Kümpfel, T | 1 |
| Aktas, O | 1 |
| Hartung, HP | 1 |
| Ringelstein, M | 1 |
| Geis, C | 1 |
| Kleinschnitz, C | 1 |
| Berthele, A | 1 |
| Hemmer, B | 1 |
| Angstwurm, K | 1 |
| Young, KL | 1 |
| Schuster, S | 1 |
| Stangel, M | 1 |
| Lauda, F | 1 |
| Tumani, H | 1 |
| Mayer, C | 1 |
| Zeltner, L | 1 |
| Ziemann, U | 1 |
| Linker, RA | 1 |
| Schwab, M | 1 |
| Marziniak, M | 1 |
| Then Bergh, F | 1 |
| Hofstadt-van Oy, U | 1 |
| Neuhaus, O | 1 |
| Zettl, U | 1 |
| Faiss, J | 1 |
| Wildemann, B | 1 |
| Paul, F | 1 |
| Jarius, S | 1 |
| Trebst, C | 1 |
| Kleiter, I | 1 |
| Enriquez, CAG | 1 |
| Espiritu, AI | 1 |
| Pasco, PMD | 1 |
| Frau, J | 1 |
| Coghe, G | 1 |
| Lorefice, L | 1 |
| Fenu, G | 1 |
| Cocco, E | 1 |
| Vitaliti, G | 1 |
| Tabatabaie, O | 1 |
| Matin, N | 1 |
| Ledda, C | 1 |
| Pavone, P | 1 |
| Lubrano, R | 1 |
| Serra, A | 1 |
| Di Mauro, P | 1 |
| Cocuzza, S | 1 |
| Falsaperla, R | 1 |
| Cree, B | 1 |
| Saida, T | 1 |
| Kim, W | 2 |
| Park, MS | 1 |
| Sohn, EH | 1 |
| Li, XF | 2 |
| Kitley, JL | 1 |
| Leite, MI | 1 |
| Matthews, LA | 1 |
| Palace, J | 1 |
| Nakano, H | 1 |
| Motoyama, R | 1 |
| Tanaka, K | 1 |
| Tanaka, M | 1 |
| Jung, IJ | 1 |
| Olindo, S | 1 |
| Marignier, R | 1 |
| Jeannin, S | 1 |
| Merle, H | 1 |
| Smadja, D | 1 |
| Weinstock-Guttman, B | 1 |
| Ramanathan, M | 1 |
| Lincoff, N | 1 |
| Napoli, SQ | 1 |
| Sharma, J | 1 |
| Feichter, J | 1 |
| Bakshi, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders[NCT02021825] | Phase 4 | 50 participants (Anticipated) | Interventional | 2009-03-31 | Recruiting | ||
| A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)[NCT00304291] | Phase 4 | 5 participants | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for mitoxantrone and Devic Disease
| Article | Year |
|---|---|
Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
Topics: Cardiomyopathies; Disease Progression; Epidemiologic Studies; Humans; Immunosuppressive Agents; Infe | 2019 |
The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.
Topics: Autoimmune Diseases; Child; Chorea; Cyclophosphamide; Guillain-Barre Syndrome; Humans; Immunoglobuli | 2015 |
Neuromyelitis optica: diagnosis, pathogenesis, and treatment.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Specificity; Aquap | 2008 |
[Treatment of NMO].
Topics: Acute-Phase Reaction; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; | 2009 |
1 trial available for mitoxantrone and Devic Disease
| Article | Year |
|---|---|
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
Topics: Adult; Antineoplastic Agents; Central Nervous System; Disability Evaluation; Female; Humans; Injecti | 2006 |
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
Topics: Adult; Antineoplastic Agents; Central Nervous System; Disability Evaluation; Female; Humans; Injecti | 2006 |
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
Topics: Adult; Antineoplastic Agents; Central Nervous System; Disability Evaluation; Female; Humans; Injecti | 2006 |
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
Topics: Adult; Antineoplastic Agents; Central Nervous System; Disability Evaluation; Female; Humans; Injecti | 2006 |
9 other studies available for mitoxantrone and Devic Disease
| Article | Year |
|---|---|
Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders: A 14-Year Real-Life Experience.
Topics: Agammaglobulinemia; Humans; Immunoglobulin G; Immunologic Factors; Mitoxantrone; Neuromyelitis Optic | 2022 |
Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean.
Topics: Caribbean Region; Humans; Mitoxantrone; Neuromyelitis Optica; Prospective Studies; Recurrence | 2024 |
Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.
Topics: Adult; Aquaporin 4; Autoantibodies; Azathioprine; Cohort Studies; Female; Follow-Up Studies; Germany | 2017 |
Long-term benefits of induction therapy in NMO: a case report.
Topics: Antibodies, Monoclonal, Murine-Derived; Diagnosis, Differential; Diagnostic Errors; Female; Humans; | 2014 |
Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica.
Topics: Adult; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Mit | 2011 |
Use of mitoxantrone in neuromyelitis optica.
Topics: Female; Humans; Male; Mitoxantrone; Neuromyelitis Optica | 2011 |
[A case of neuromyelitis optica with varicella zoster virus meningitis during mitoxantrone treatment].
Topics: Adult; Female; Herpes Zoster; Humans; Meningitis, Viral; Mitoxantrone; Neuromyelitis Optica; Virus A | 2011 |
Clinical spectrum of CNS aquaporin-4 autoimmunity.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Aquaporin 4; Autoantibodies; Autoimmunity; Azathiopri | 2012 |
Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Cohort Studies; Disability Evaluation; Disea | 2013 |